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Due to the shortage of liver allografts and the rising prevalence of fatty liver disease in the general population, steatotic liver grafts are
considered for transplantation.This condition is an important risk factor for the outcome after transplantation. We here analyze the
characteristics of the donor pool offered to the Charite´ – Universita¨tsmedizin Berlin from 2010 to 2016 with respect to liver allograft
nonacceptance and steatosis hepatis. Of the 2653 organs offered to our center, 19.9% (n=527) were accepted for transplantation,
58.8% (n=1561) were allocated to other centers, and 21.3% (n = 565) were eventually discarded from transplantation. In parallel
to an increase of the incidence of steatosis hepatis in the donor pool from 20% in 2010 to 30% in 2016, the acceptance rates for
steatotic organs increased in our center from 22.3% to 51.5% in 2016 (p < 0.001), with the majority (86.9%; p > 0.001) having less
than 30% macrovesicular steatosis hepatis. However, by 2016, the number of canceled transplantations due to higher grades of
steatosis hepatis had significantly increased from 14.7% (n = 15) to 63.6% (42; p < 0.001). The rising prevalence of steatosis hepatis
in the donor pool has led to higher acceptance rates of steatotic allografts. Nonetheless, steatosis hepatis remains a predominant
phenomenon in discarded organs necessitating future concepts such as organ reconditioning to increase graft utilization.
1. Introduction
Orthotopic liver transplantation (OLT), which is the only
curative therapy option in patients with end-stage liver dis-
ease, is increasingly limited by the discrepancy between organ
demand and availability [1, 2]. Donation after cardiac death,
split-liver transplantation, living donor liver transplantation,
and transplantation of grafts from extended criteria donors
have been developed to expand the donor pool [3, 4]. In spite
of these developments, and due to the increase in donor age
and stagnation of donations, the number of patients on the
waiting list constantly exceeds the organ supply [5].While the
number of liver transplantations decreased, more restrictive
listing policies have led to sicker patients on the waiting list,
with high rates of mortality and impaired outcome after liver
transplantation [6–8].
Steatosis hepatis, also known as fatty liver disease, is
considered an important risk factor for graft dysfunction
after liver transplantation, and more than 50% of grafts with
histologically confirmed moderate or severe macrosteatosis
are usually not used for transplantation [9]. Nonalcoholic
fatty liver disease, which is the hepatic manifestation of the
metabolic syndrome, is already the second most common
cause for liver transplantation in the USA and currently the
only increasing etiology with increasing incidence [10–13].
With the rising prevalence of steatosis hepatis in potential
donors, graftutilization is expected to fall from78% to 44%by
2030 [10]. However, data on the current nonacceptance rate
Hindawi
HPB Surgery
Volume 2018, Article ID 6094936, 9 pages
https://doi.org/10.1155/2018/6094936
2 HPB Surgery
of liver grafts due to steatosis hepatis in the Eurotransplant
region are not well documented in the literature. Based
on large retrospective database analyses, transplantation of
liver grafts with macrovesicular steatosis > 30% is only
recommended from donors with less overall risk factors [14,
15]. Even though macrovesicular steatosis is a recognized
risk factor for primary nonfunction and early allograft
dysfunction (EAD) [14–21], the extent of the postoperative
impairment remains disputed. It is generally accepted that
severe macrovesicular steatosis ≥ 60% leads to higher rates of
primary nonfunction and EAD, and to reduced 1- and 3-year
recipient and graft survival [16, 22, 23], while mild steatotic
organs seem to be safe to transplant [14, 15, 24].
Germany in particular has seen a drastic 30% decline in
organ donation, from 1200 donors in 2011 to only 857 donors
in 2016.This aggravates the need to offer grafts fromextended
criteria donors to meet the demand for liver allografts. The
question arises if expanding the donor pool with such donors
has actually yielded higher rates of transplantations or just
higher rates of notaccepted livers. To address this question
and to update the knowledge concerning liver graft utiliza-
tion and reasons for nonacceptance in the Eurotransplant
region [25], we here analyzed all grafts offered to our high-
volume center from 2010 to 2016 with regard to allocation,
i.e., acceptance, nonacceptance, or discarded organs, with a
special focus on grafts with steatosis hepatis.
2. Materials and Methods
2.1. Study Site and Ethical Board Approval. This single
center retrospective data analysis was performed in the
Department of Surgery, Campus Charite´ Mitte | Campus
Virchow-Klinikum of the Charite´ – Universita¨tsmedizin
Berlin (Berlin, Germany). The study protocol was approved
by the local ethics committee (Ethics committee of the
Charite´, EA2/010/17).
2.2. Organ Offers. Data for all livers from 2010 to 2016 offered
by Eurotransplant to the Charite´ – Universita¨tsmedizin
Berlin was requested from Eurotransplant and analyzed.
All donors included in the analysis were from brain death
donors (DBD). Donor data included in analysis were
donor age, body mass index (BMI), hepatitis B (HBV)
status, hepatitis C (HCV) status, aspartate-aminotransferase
(AST), alanine-aminotransferase (ALT), gamma-glutamyl
transferase (GGT), international normalized ratio (INR), c-
reactive protein (CRP), creatinine, sodium, history of dia-
betes mellitus, or smoking, cardiopulmonary resuscitation,
cause of death, duration of intensive care unit (ICU) stay,
signs for steatosis hepatis in ultrasonography, steatosis hep-
atis in histopathology report, and the allocation phase, i.e.,
whether the offered donor liver was procured or transplanted
at all.
2.3. Organ Acceptance. All liver offers made to the Charite´
– Universita¨tsmedizin Berlin are recorded and in case of
nonacceptance the reason is remarked. Clinic records were
screened from 2010 to 2016. Reason of nonacceptance was
categorized into “donor medical,” “weight/size,” “recipient
medical,” “logistics,” or “other reasons.” “Donor medical”
was further subclassified into “age,” “biochemical param-
eters,” “cardiopulmonary resuscitation,” “steatosis hepatis,”
“infection,” “malignancy,” “substance abuse,” “ICU stay,” or
“other reasons.” Liver allografts were accepted on a case-
by-case basis for each individual patient, considering donor
age, weight, and size relative to recipient age, as well as the
virologic status of the donor (especially HCV and human
immunodeficiency virus). Additionally, the expected cold
ischemia time (CIT) and the presence of steatosis hepatis
influenced the acceptance decision.
2.4. Classification of Steatosis Hepatis. Steatosis hepatis is
classified into two groups: (I) any description of steatosis
hepatis, i.e., ultrasound or histopathological report; (II) cases
with histopathological confirmation. The histopathological
confirmed cases were further graded by the degree of
macrovesicular steatosis hepatis as previously reported by
Chu et al. and Bricen˜o et al. [24, 26]. Macrovesicular steatosis
< 5% was classified as “no steatosis,” followed by < 30% as
“mild steatosis,” ≥ 30% as “moderate steatosis,” and ≥ 60%
as “severe steatosis.” In addition, 1-year graft and recipient
survival rates were calculated. Graft survival was defined as
the absence of recipient death or retransplantation. Early
allograft dysfunction was calculated for all recipients and
defined as bilirubin ≥ 10mg/dl or INR ≥ 1.6 on POD 7 or
AST/ALT >2000 IU/l during the first 7 days [17].
2.5. Statistical Analysis. Data is presented as mean± standard
deviation (SD) for normal distribution of data. Not normally
distributed data is reported in median and interquartile
range. Categorical variables were measured in proportions
and counts. After testing for normality, continuous para-
metric variables were analyzed with the Student’s t-test and
nonparametric variables using the Wilcoxon rank-sum test.
Grouped variables were analyzed with the one-way ANOVA
or the Kruskal-Wallis test according to normality. Categorical
variables were analyzed using the Pearson 𝜒2 test.
A binary logistic regression analysis for liver acceptance
was carried out. Age was classified into groups of <50 years
and above 50 into decades: 50-59, 60-69, 70-79, and >80.
BMI was classified in a similar way: < 18.5, 18.5-24.9, 25-
29.9, 30-34.9, 35-39.9, and >40. All reported P values are two-
sided; overall a P value < 0.05 was considered significant.
Graphs were plotted using GraphPad Prism Version 6.04
for Macintosh (GraphPad Software, La Jolla, CA, USA) and
calculations were carried out using IBM SPSS Statistics for
Macintosh Version 24.0 (IBM Corp., Armonk, NY, USA).
3. Results
3.1. Increasing Number of Cancelled Transplantations. From
2010 to 2016 liver grafts from 2653 donors were offered to
the Charite´ – Universita¨tsmedizin Berlin. Organs from 527
donors (19.9%) were accepted and successfully transplanted
(Figure 1(a)). From the remaining 2126 (80.1%) of offered
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Figure 1: Organs offered and accepted 2010-2016. (a) All liver allografts offered to our center, accepted and not accepted. (b) All nonaccepted
liver allografts, secondary allocation to another center or discarded from allocation.
other centers and 565 (26.6%) donors could not be allocated
and were not used for transplantation (Figure 1(b)). Of all
organs not used for transplantation, 304 (53.8%) were not
procured at all.
At our center the number of livers accepted and trans-
planted significantly decreased (p < 0.001) from 2010 (102,
i.e., 32.9%) to 2016 (66, i.e., 10.9%), while the number of
nonaccepted organ offers more than doubled (208 and 536,
respectively) in the same time period. Although the number
of patients awaiting OLT at our center decreased from 157 in
2010 to 98 in 2016, respectively, there weremore overall offers.
3.2. Reasons for LiverAllograftNonacceptance. Medical issues
of the donors, such as age, biochemical parameters, or steato-
sis hepatis, were the primary reason for graft nonacceptance.
Steatosis hepatis, as reported by the explant surgeon based
on macroscopic or histopathological assessment of the graft,
did not differ significantly from 2010 (15.0%) to 2016 (11.8%),
but the number of cancelled liver transplantations due to
macrovesicular steatosis hepatis of the graft significantly
increased from 2010 to 2016 (p < 0.001) from 15 to 42.
3.3. Donors of Discarded Organs Are Older and Present with
Higher Rates of Steatosis Hepatis. In analysis of allocation
groups, i.e., transplanted in our center, allocated elsewhere,
or discarded, age differed significantly across groups with
discarded organs having the highest age (56.0 ± 21.3, p <
0.001). In regard to steatosis hepatis, 49.7% of discarded
organs had reports of steatosis hepatis compared to 28.3%
transplanted at our center and 27% transplanted elsewhere
after secondary allocation (Figure 2(b)). Age and steatosis
hepatis were significantly associated (p < 0.001); almost half
of donors (45.2%) above the age of 65 had reports of steatosis
hepatis, compared to 26.5% in donors under the age of 65
(Figure 2(a)).
Cause of death due to trauma was the least likely cause
for organs to be discarded 12.6% vs. 15.9%, 19.8, respectively, p
< 0.001). Furthermore, the laboratory parameters AST, GGT,
bilirubin, INR, and creatinine were all significantly higher (p
< 0.001) in the group of discarded organs (Table 1).
3.4. Increasing Prevalence of Steatosis Hepatis in Accepted
Organs. From 2010 to 2016 the proportion of accepted and
transplanted steatotic livers increased significantly (p < 0.001,
Figures 3(a) and 3(b)). While 22.3% (n = 22) of livers
transplanted in 2010 had evidence of steatosis hepatis, this
number rose to 51.5 % (n = 66) by 2016. During the same
time the proportion of discarded organs which were steatotic
significantly decreased (p = 0.04) from 61.2% (n = 30) in 2010
to 46.8% (n=66) in 2016. In the overall offered donor pool,
steatosis hepatis differed in between years (p = 0.007), with
an increase of the prevalence from 24.0% in 2013 to 34.7% in
2016 (Figure 3(c)).
3.5. Histopathological Reports of Steatosis Hepatis Influence
Acceptance Rates. Histopathological reports of donors were
available in 28.9% (n = 766) of cases. In discarded liver grafts
42.5% of organs had a pathology report present compared to
only in 24.7% in transplanted liver grafts. Moderate or severe
steatosis hepatis was present in discarded organs in 43.8% (n
= 105) of cases with 17.5% (n = 42) of those being severely










































Figure 2: Age and steatosis as influencing factors of acceptance rates. (a) Significantly higher proportion of discarded liver allografts from
senior donors (39.1%∗∗∗ p < 0.001). (b) Steatosis hepatis is significantly more frequently present in discarded organs (49.7%, ∗∗∗ p < 0.001).
Table 1: Donor data overview.
Total Allocated Transplanted Discarded P value
N 2653 1561 527 565
Gender (m) (n, %) 1418 (53.5) 816 (52.3) 268 (51.0) 334 (59.3) 0.007
Age1 51.3 ± 20.6 49.0 ± 20.8 53.25 ± 18.2 56.0 ± 21.3 < 0.001
Cause of Death < 0.001
Trauma (n, %) 464 (17.5) 309 (19.8) 84 (15.9) 71 (12.6)
Cerebrovascular (n, %) 1308 (49.3) 716 (45.9) 288 (54.6) 304 (53.8)
Anoxia (n, %) 379 (14.3) 219 (14.0) 74 (14.0) 86 (15.2)
Other (n, %) 502 (18.9) 317 (20.3) 81 (15.4) 104 (18.4)
BMI (kg/m2)1 25.5 ± 4.9 25.0 ± 4.3 25.6 ± 4.6 26.8 ± 6.3 < 0.001
ICU stay (days)2 3.0 (5) 3 (5) 3 (6) 3 (4) 0.25
AST (U/l)2 52.0 (76) 49.0 (71) 47.0 (78) 64.5 (102) < 0.001
ALT (U/l)2 34.0 (60) 34.0 (57) 34.0 (59) 36 (70) 0.08
GGT (U/l)2 44.0 (93) 39.0 (78) 47.0 (100) 70.0 (161) < 0.001
Bilirubin (𝜇mol/l)2 8.7 (10) 8.2 (10) 9.2 (10) 12.0 (14) < 0.001
INR2 1.18 (02.4) 1.16 (0.25) 1.19 (0.27) 1.2 (0.29) < 0.001
Creatinine (𝜇mol/l)2 70.7 (57.3) 68.0 (55.75) 73.2 (51.85) 79.8 (68.58) < 0.001
CRP (mg/l)2 139.9 (162.65) 136.8 (164.75) 142.5 (152.4) 143.6 (175.23) 0.29
Na++ (mmol/l)2 148.0 (76.0) 148.0 (11) 147.0 (10) 148.0 (12) 0.15




828 (32.1) 409 (27.0) 146 (28.3) 273 (49.7) < 0.001
Steatosis Hepatis confirmed
only in pathology (n, %) 665 (26.6) 334 (22.4) 114 (22.9) 217 (42.4) < 0.001
1Data is presented as mean ± standard deviation. 2Data is presented as median (interquartile range). Abbreviations: ALT: alanine-aminotransferase; AST:
aspartate-aminotransferase; BMI: body mass index; CPR: cardiopulmonary resuscitation; CRP: C-reactive protein; GGT: gamma-glutamyl transferase; ICU:














































































































Figure 3: Steatosis hepatis prelavence and influence on acceptance rates. (a) Declining acceptance rate for all liver allografts during study
period (∗ ∗ ∗ p < 0.001). (b) Significant increase in steatosis hepatis in transplantations in our center (∗ ∗ ∗ p < 0.001). (c) Trend in rising
steatosis hepatis prevalence in donor population after 2012.
Table 2: Steatosis hepatis in donors with available histopathological report.
Organs Discarded Transplanted P value
n 240 526
No Steatosis Hepatis (n, %) 42 (17.5%) 183 (34.8%)
< 0.001Mild Steatosis (n, %) 93 (38.8%) 274 (52.1%)
Moderate Steatosis (n, %) 63 (26.3%) 50 (9.5%)
Severe Steatosis (n, %) 42 (17.5%) 19 (3.6%)
Data is presented as counts (proportions).
3.6. Steatosis Hepatis Is a Significant Predictor of Liver Nonuse
in Multivariate Model. A logistic regression was performed
to determine the effects of age, BMI, cause of death, history of
smoking and/or diabetes, blood levels of AST, GGT, bilirubin,
INR, creatinine, HCV, HBV, and steatosis hepatis on the
probability of liver grafts being accepted for transplantation.
The created model was statistically significant 𝜒2 = 226.25 p
< 0.001 and explained 28.0% (Nagelkerke R2) of the variance
in organ acceptance while correctly classifying 79.7% of cases
(Table 3). Donor age below 50 was a significant predictor of
organ acceptance (p = 0.004, OR = 2.77, 95% CI = 1.29-5.53);
ages above 50 were not significantly associated with organ
acceptance. In cases of normal or overweight donor BMI this
was equally the case (normalweight: p = 0.001,OR= 7.32, 95%
CI = 2.26-3.3; overweight: p = 0.003, OR = 5.6, 95%CI = 1.77-
7.73). Compared to donors with positive HCV antibodies, the
odds for acceptance were highest in cases of donors being
negative for HCV antibodies (p < 0.001, OR = 11.79, 95% CI
= 4.49-30.93)
Additionally, lack of steatosis hepatis increased odds for
acceptance significantly (p < 0.001, OR = 1.88, 95% CI = 1.33-
2.65). Relevant biochemical parameters were levels of AST,
GGT, bilirubin, and INR which all presented increased odds
for organ acceptance with lower values.
A similar logistic regression was performed with all
caseswith available histopathological reports.Thismodelwas
statistically significant 𝜒2(4) = 119.19, p < 0.001 and explained
40.2% (Nagelkerke R2) of the variance in organ acceptance
while correctly classifying 78.8% of cases. Macrovesicular
steatosis of the graft below 5% was associated with higher
organ acceptance (p < 0.001; OR 16.68, 95% CI = 5.01–55.43).
In this model only blood levels of creatinine, AST, bilirubin,
HCV status, and age were significantly associated with organ
acceptance.
3.7. Macrovesicular Steatosis Is Predictive for EAD after Trans-
plantation. The incidence of EAD significantly increased
(p = 0.013) with regard to the degree of macrovesicular
steatosis of the graft. EAD occurred in 13 recipients (21.3%)
of grafts with no steatosis, 23 patients (39.0%) that received
grafts with mild macrovesicular steatosis, and 9 recipients
(56.3%) of grafts with moderate and severe macrovesicular
steatosis (Figure 4(a)). Cold ischemia time greater than 8
hours combined with moderate macrovesicular steatosis led
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Table 3: Multivariate logistic regression of organ acceptance.
Organ Acceptance
P value OR (95% CI)
Age (years)
< 50 0.004 2.77 (1.29; 5.53)
50 – 59 0.372 1.34 (0.68; 2.80)
60 – 69 0.172 1.63 (0.81; 3.30)
70 – 79 0.567 1.22 (0.62; 2.37)
>80 Reference
BMI
< 18.5 0.50 1.62 (0.40; 6.52)
18.5 – 24.9 0.001 7.32 (2.26; 23.77)
25.0 – 29.9 0.003 5.60 (1.77; 17.73)
30 – 34.9 0.12 2.56 (0.78; 8.41)
35 – 39.9 0.51 1.61 (0.40; 6.55)
≥ 40.0 Reference
Cause of Death
Trauma 0.76 1.72 (0.94; 3.14)
Cerebrovascular Accident 0.72 1.09 (0.68; 1.73)
Anoxia 0.12 1.61 (0.88; 2.94)
Other Reference
Smoking (yes) 0.4 1.12 (0.82; 1.67)
Diabetes mellitus (yes) 0.88 0.96 (0.59; 1.57)
No Steatosis hepatis < 0.001 1.88 (1.33; 2.65)
HCV antibody negative < 0.001 11.79 (4.49; 30.93)
HBV core antibody negative 0.09 1.62 (0.94; 2.81)
AST 0.01 1.0 (1.0; 1.0)
GGT < 0.001 1.0 (1.0; 1.0)
Bilirubin < 0.001 0.97 (0.96; 0.98)
INR 0.04 0.79 (0.62; 0.99)
Creatinine 0.47 1.0 (1.0; 1.0)
Na+ 0.07 0.98 (0.96; 1.0)
CRP 0.76 1.0 (1.0; 1.0)
Data is presented as odds ratios (OR) and 95% confidence intervals (CI). Abbreviations: AST: aspartate-aminotransferase; BMI: body mass index; CRP: C-
reactive protein; GGT: gamma-glutamyl transferase; HBV: hepatitis B virus; HCV: hepatitis C virus; INR: international normalized ratio; Na+: serum sodium.
to EAD in 9 (69.2%) cases compared to 28 (30.4%) cases
with cold ischemia time less than 8 hours (p = 0.006). EAD
led to significantly decreased 1-year recipient (p < 0.001)
and graft survival (p < 0.001) (Figure 4(b)). In univariate
analysis, severe macrovesicular steatosis compared to any
other grades of steatosis or no steatosis had a significant effect
on 1-year graft survival (p = 0.03; 33.3% vs. 75%) and recipient
survival (p = 0.04; 33.3% vs 72.0%), while lower degrees of
macrovesicular steatosis had no effect on graft survival (p =
0.13, Figure 4(c)).
4. Discussion
The increasing shortage of suitable organs for transplantation
necessitates constant reevaluation and expansion of organ
acceptance criteria. The results of our study show a steady
increase in the overall number of liver graft offers but a
decline in the acceptance rate from 2010 to 2016.The increase
in the number of organs offered to our center is in huge
discrepancy with the factual number of organ donations
in the Eurotransplant region and the decreasing number of
realized liver transplantations. This trend can be explained by
multiple or repeating offers ofmarginal organs fromextended
criteria donors to different transplant centers and may be
attributed to amore restrictive policy for acceptance of organs
from extended criteria donors for high-MELD patients,
which are prioritized in the Eurotransplant allocation system.
Steatosis hepatis is a critical factor for declining an
organ offer. The rising prevalence of steatosis hepatis in the
general population is well documented [27, 28]: The overall
prevalence today is between 20% and 30% in Europe and 46%
in the United States [10, 29]. De Graaf et al. reported a rate
of 62% microvesicular and 38% macrovesicular steatosis in
liver allografts from deceased donors from 2001 to 2007 in
Australia [16]. Among potential living donors, the prevalence
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Figure 4: Steatosis hepatis prelavence and influence on graft survival. (a) Increased rates of EAD in steatotic liver grafts (p = 0.013). (b)
Kaplan-Meier analysis of graft survival of patients with and without early allograft dysfunction (EAD) (p < 0.001). (c) Kaplan-Meier analysis
of graft survival in steatotic liver grafts (p = 0.13). S0, no steatosis; S1, mild steatosis; S2, moderate steatosis; S3, severe steatosis. EAD, early
allograft dysfunction.
15% to 53% in different studies and disqualified 3% to 21% of
potential liver grafts [10]. In contrast, the extent of steatosis
on the nonacceptance rate of donated livers is not well
documented in the literature. Of note, such an evaluation
is limited by the fact that there is no standardized protocol
for evaluation of steatosis hepatis of potential liver grafts.
The assessment of liver steatosis in potential deceased donors
is usually limited to the sonographic inspection or analysis
in computed tomography scans. Histopathological verifica-
tion cannot be performed on a routine basis in hospitals
conducting organ retrieval due to logistic reasons. Even
though, in our cohort, if steatosis hepatis was reported from
ultrasound or macroscopic examination, it was confirmed in
92.5% of cases with a histopathological analysis, nevertheless,
liver grafts are rejected by the transplant center based on
a nonstandardized assessment of steatosis hepatis. We here
show that even though the proportion of steatotic donor
organs transplanted in our recipients increased significantly
from 2013 to 2016, 42 liver grafts were still rejected due to
steatosis hepatis in 2016, which accounted for a potential
increase of 63.6% liver transplantations not transplanted
due to steatosis of the graft. Compared to 2010, this rate
of not-realized transplantations increased by 49%. Efforts
to counteract steatosis hepatis are therefore of immediate
clinical relevance and should be therapeutically targeted, e.g.,
by conditioning of steatotic liver grafts by machine perfusion
during the preservation period [30].
Our evaluation of reason for nonacceptance confirms
previous reports from Orman et al. concerning age and
BMI [9]. However, the history of diabetes mellitus was not
significantly associated with organ acceptance in our study
cohort.The effect of DCD donors on acceptance could not be
investigated, as transplantation in Germany is strictly DBD
donors only. Additionally, we could show that a significantly
larger proportion of steatotic organs were discarded and
that prevalence of steatosis hepatis increased over time.
In multivariate analysis, we found a significant trend to
declining organs with moderate or severe macrovesicular
steatosis and a positive trend for acceptance of organs with
macrovesicular steatosis hepatis levels below 30%.
Interestingly enough steatosis hepatis coincided with
major limitations in organ quality such as increased liver
injury parameters and decreased renal function parameters.
Donors with steatosis hepatis also had increased ICU stay
duration and were older. This combination is challenging,
as each factor for itself is known to negatively impact
survival after liver transplantation [15, 31, 32]. Unlike in the
United States, recipient survival after liver transplantation has
been worse since the introduction of the MELD score [33–
35]. Irregularities uncovered in the German liver allocation
program since 2012 have changed the donor pool and led to
fewer suitable donors and reduced overall organ quality [33].
Our data on graft acceptance rate reflects this trend and shows
a 21.8% drop of acceptance from 2010 to 2016, while organ
offer numbers doubled in the same time.
Our evaluation of the outcome of macrovesicular liver
grafts confirms previous reports, showing significantly higher
rates of EAD compared to grafts with no steatosis. Unlike
previously reported [16, 23, 36], we observed this effect
not only for severe but also for mild and moderate steatotic
grafts. However, the definition of EAD is not standardized. As
previously reported fromWesterkamp et al., the combination
of long CIT and moderate or severe macrovesicular steatosis
had detrimental effects on the outcome after transplantation
[37]. These effects, which we already observe in grafts with
mild steatosis, could demand adapted allocation and preser-
vation procedures to reduce CIT and subsequently reduce
expected ischemia-reperfusion injury [18, 19].
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5. Conclusion
In conclusion, our analysis shows a significant decline in
liver allograft acceptance rate at our center. In parallel to
the increase of steatosis hepatis in the donor pool there was
a significant increase of steatosis hepatis acceptance at our
center especially in cases with histopathological confirmation
of less than 30%macrovesicular steatosis. Moreover, we show
a strong association of macrovesicular graft steatosis and the
development of EAD, especially in cases with prolonged CIT.
Although our results are limited by the retrospective and
single center analysis, we propose the present data to be at
least relevant for Germany and the Eurotransplant region,
where highMELDpatients and organs from extended criteria
donors affect the outcome of liver transplantation. Therapeu-
tic concepts are necessary to address the rising prevalence
of steatotic grafts and the inferior outcome associated with
transplantation of such grafts. These concepts should range
from limiting the effects of cold ischemia to the graft by ex
vivo machine perfusion to the metabolic reconditioning of




BMI: Body mass index
CPR: Cardiopulmonary resuscitation
CRP: C-reactive protein
DBD: Donation after brain death
DCD: Donation after cardiac death
EAD: Early allograft dysfunction
GGT: Gamma-glutamyl transferase
HCV: Hepatitis C virus
HBV: Hepatitis B virus
ICU: Intensive care unit
INR: International normalized ratio
IQR: Interquartile range
OLT: Orthotopic liver transplantation
SD: Standard deviation
UNOS: United Network for Organ Sharing.
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